Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹99 | ₹100 |
Expense Ratio | 1.65 | 1.36 |
NAV | ₹38.13 | ₹202.57 |
Fund Started | 08 Jul 2019 | 07 May 2007 |
Fund Size | ₹17194.25 Cr | ₹84854.73 Cr |
Exit Load | Exit Load for units in excess of 15% of the investment,1% will be charged for redemption within 1 years. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 9.70% | 9.49% |
3 Year | 20.54% | 25.54% |
5 Year | 26.15% | 29.55% |
1 Year
3 Year
5 Year
Equity | 98.81% | 93.60% |
Cash | 1.19% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Lupin Ltd. | 3.01% |
Cummins India Ltd. | 2.94% |
Delhivery Ltd. | 2.85% |
Tata Communications Ltd. | 2.69% |
Bharat Forge Ltd. | 2.57% |
L&T Finance Ltd. | 2.51% |
Hero Motocorp Ltd. | 2.39% |
Voltas Ltd. | 2.31% |
Dalmia Bharat Ltd. | 2.30% |
Swiggy Ltd. | 2.28% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Ankit Jain | Chirag Setalvad |
Start Date | 05 Oct 2016 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation from a portfolio investing predominantly in Indian equity and equity related securities of midcap companies. From time to time, the fund manager may also participate in other Indian equities and equity related securities for optimal portfolio construction. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 08 Jul 2019 | 07 May 2007 |
Description
Launch Date